By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) Announces FDA Approval Of Dysport(Abobotulinumtoxina) For Injection In The Treatment Of Upper Limb Spasticity In Adults In The United States 7/17/2015 9:17:28 AM
Ipsen (IPN.PA) Provides An Update On 2020 Strategy And Outlook At Investor Day 7/2/2015 11:18:20 AM
Ipsen (IPN.PA) Initiates A Share Buyback Program 6/3/2015 8:50:48 AM
Ipsen (IPN.PA) Confirms Its Eligibility For PEA-PME 6/2/2015 12:39:13 PM
Combined Shareholders’ Meeting Of IPSEN S.A. Held On 27 May 2015 5/29/2015 11:27:16 AM
Ipsen (IPN.PA) Strengthens Its Presence In The Oncology Field With The Acquisition Of Octreopharm Sciences, A Company Developing Innovative Radiopharmaceuticals For The Diagnosis And Treatment Of Neuroendocrine Tumors 5/19/2015 11:01:50 AM
Ipsen (IPN.PA) Announces Data Presentations For Somatuline Depot (lanreotide) In Gastroenteropancreatic Neuroendocrine Tumors At ASCO Annual Meeting 5/14/2015 12:35:04 PM
Ipsen (IPN.PA) Reports Strong Sales Growth In Q1 2015 And Raises Guidance For The Year 4/29/2015 12:18:38 PM
Ipsen (IPN.PA), Active Biotech AB (BTPC) Plummet As Prostate Cancer Drug Flunks Late-Stage Trial 4/16/2015 10:23:37 AM
Ipsen (IPN.PA) And Hannover Medical School Start Joint Research In Recombinant Botulinum Neurotoxins For Targeted Secretion Inhibitors 4/8/2015 11:31:34 AM